DSGN (Design Therapeutics Inc) Net earnings per share for the last 12 months

Symbol and logo of brand Design Therapeutics (DSGN)

Design Therapeutics (DSGN) shares are under pressure from capital dilution risks and uncertainty surrounding early-stage tests. Net income per share reflects a local trend, with the metric currently standing at -1.20. The strategy of developing small molecules for rare pathologies provides pricing power, while a diversified approach to genetic diseases reduces the likelihood of fatal research failures.

Design Corp (DSGN) - Earnings per share for the last four quarters from 07/04/2022 to 11/14/2026

Analytical breakdowns and data insights for company Design Therapeutics Inc (DSGN)

- current quotes and average value forecast:
Price Chart Design Therapeutics|DSGN - Broker Consensus Forecast
- business market valuation indicators:
Market Valuation Design Therapeutics, Inc.|DSGN - Value Adjusted for Debt and Cash
- balance sheet net asset value indicators:
Accounting Value per Share Design Therapeutics|DSGN - Total Net Assets|Market Capitalization to Book Value Ratio designtx.com|DSGN - Aggregate Asset Value
- debt obligations and liquidity statistics:
Total Debt to Capital Design Therapeutics|DSGN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Design Pharma|DSGN - Aggregate Debt Obligations|Debts to Book Capitalization Design Therapeutics, Inc.|DSGN - Company Long-Term Debts|Company Short-Term Debt Design Therapeutics|Quick Ratio designtx.com
- earnings and valuation multiples indicators:
DSGN - Company Net Income|Future Profit Design Therapeutics|DSGN - P/E Multiple|Projected Price to Earnings Design Therapeutics, Inc.|DSGN - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Design Therapeutics, Inc.|DSGN - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Design Therapeutics|DSGN - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months designtx.com|DSGN - Expected net earnings per share growth this year|Earnings growth forecast for next year Design Therapeutics
- sales revenue and business income indicators:
DSGN - Company Sales Volume|Company Projected Revenue Design Therapeutics|DSGN - Price-to-Revenue Coefficient|Forward P/S Multiple Design Therapeutics, Inc.
General company analysis:Design Therapeutics (DSGN)
Manufactured products of Design Pharma

Design Therapeutics focuses on developing small molecules for the therapy of severe genetic pathologies with the expectation of reimbursement from insurance funds. Analyzing the trend of the rolling annual earnings per share allows for the elimination of the impact of securities issuance and an assessment of real business efficiency by excluding reporting time lags, which helps determine the fundamental stability of the asset's quotes.

Competitors of Design Therapeutics (DSGN)

TEM - Earnings per share for the last twelve months|QGEN (qiagen.com) - Earnings per share for the last 12 months|IONS (Ionis) - Net earnings per share for the last 12 months|Repligen Corp - Earnings per share for the trailing year|Net earnings per share for the last 12 months RNA|CRSP (CRISPR) - Earnings per share for the last four quarters|Net earnings per share (EPS TTM) WGS|RARE (ultragenyx.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) BEAM (Beam Therapeutics)|Sarepta Therapeutics (SRPT) - Net earnings per one share for the last twelve months|TWST - Earnings per share for the last twelve months|Earnings per share for the trailing year TXG (10x)|NTLA: Net earnings per share (EPS TTM)|stoketherapeutics.com (STOK) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months BioLife Solutions|Wave Life Sciences Ltd - Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) MAZE|SION - Net earnings per one share for the last twelve months|Prime Medicine, Inc. - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) tayshagtx.com TSHA|QURE: Net earnings per share for the last 12 months|MeiraGTx Holdings - Earnings per share for the last four quarters|RGNX: Net earnings per share (EPS TTM)|SLDB - Net earnings per share for the last four quarters|OCGN (Ocugen, Inc.) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months pacb.com (PACB)|Earnings per share for the last twelve months Benitec Biopharma (BNTC)|Net earnings per share for the last four quarters Rocket Pharma|Net earnings per share (EPS TTM) FDMT (4D Molecular Therapeutics Inc)|LXEO: Earnings per share for the last 12 months|KRRO - Earnings per share for the last twelve months|Net earnings per share for the last four quarters editasmedicine.com EDIT|SLN: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year ProQR Therapeutics PRQR|Earnings per share for the last twelve months Codexis Inc|Earnings per share for the last 12 months SGMO (Sangamo BioSciences)|Net earnings per share (EPS TTM) NAUT|metagenomi.co - Earnings per share for the last 12 months|Earnings per share for the last twelve months Precision BioSciences, Inc. DTIL|GBIO: Earnings per share for the last 12 months|Boundless Bio, Inc - Net earnings per share (EPS TTM)|XCUR - Net earnings per share (EPS TTM)|IMNN: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months PHIO|MBIO (Mustang Bio Inc) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months TransCode RNAZ|Earnings per share for the last twelve months Bionano Genomics, Inc. (BNGO)|Net earnings per share for the last four quarters Applied DNA Corp|Net earnings per share (EPS TTM) BLUE (bluebird bio, Inc.)|Net earnings per share for the last four quarters ImmunoPrecise Antibodies Ltd (IPA)|Omega Therapeutics, Inc. - Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Singular Genomics Systems, Inc. (OMIC)|Regulus Therapeutics Inc (RGLS) - Earnings per share for the last twelve months|Earnings per share for the last 12 months SYRS|Net earnings per share for the last 12 months TBIO|TCON: Earnings per share for the trailing year|Net earnings per share for the last 12 months UBX (Unity Biotechnology, Inc.)